Whoopi Goldberg has warned fans about a fake advertisement, which features an AI-edited video of her endorsing a weight loss ...

The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Toyota Motor sold 10.8 million vehicles globally in 2024, retaining its position as the world's biggest carmaker. The Japanese automakers had announced a plan to combine in December. Novo's Wegovy and ...

Weight-loss jabs such as Ozempic are being hailed as a potential breakthrough in the fight against obesity. Demand, fuelled ...

Demand for weight loss injections has skyrocketed in just one year, with Google searches for the treatment rising by almost ...

With weight loss drugs such as Ozempic and Mounjaro seemingly able to melt the pounds away, you might well think you'll never need a 'diet plan' again. Alas, you'd be wrong. As a leading weight ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

A Wisconsin couple is suing Walgreens and a pharmacy benefits management company, alleging that their son died because he couldn't afford a sudden $500 spike in his asthma medication.

Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro, may be an effective alternative to painful daily treatment for a rare disorder, according to research published Jan. 29 in ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...